What Is Vinblastine? A Guide for Pet Parents

Vinblastine is a chemotherapy drug used in dogs, most often for mast cell tumors. It comes from the Madagascar periwinkle, it's given as an injection into a vein, and it works by blocking the internal scaffolding cells build in order to divide.

If the name sounds almost identical to vincristine, that's because the two drugs are chemically close relatives. They are not, however, interchangeable, and this is the single most useful thing to understand about vinblastine.

The two drugs cause different trouble. Vincristine is more associated with stomach upset, and researchers describe vinblastine as generally well tolerated by comparison (Harding et al., 2018). Vinblastine's own limiting problem is a different one: it lowers white blood cells, and that is usually what forces a dose to be reduced or a treatment postponed.

They also treat different cancers. Vincristine is the standard vinca alkaloid in the lymphoma protocol. Vinblastine is the standard one for mast cell tumors.

That isn't just convention. Researchers actually tested vinblastine as a lymphoma treatment in dogs and found it worked poorly at the standard dose, concluding that treatment at that dose was not recommended for lymphoma (Harding et al., 2018). Two drugs that look like siblings on the label behave quite differently in a patient.

The practical consequence for you is that vinblastine's main risk sits in the bloodwork rather than in how your dog seems at home. A dog whose neutrophil count has fallen can look entirely normal until they suddenly don't.

Key points

• Vinblastine is given intravenously, most often for mast cell tumors, frequently alongside prednisone or prednisolone.
• Its main limitation is myelosuppression, which means it slows the bone marrow's production of blood cells. A low white cell count is the usual reason a dose gets reduced or delayed, which is why bloodwork before each treatment isn't optional.
• In a study of 30 dogs on a vinblastine and prednisolone protocol, 24 experienced at least one blood-count abnormality, though most were low grade (Soussa et al., 2024).
• Small dogs may be more vulnerable. In 40 dogs weighing under 10 kg, neutropenia occurred in 82.5 percent after a single treatment (Matsuyama et al., 2026).
• It's a vesicant. Leakage outside the vein damages tissue, which is why catheter placement is handled so carefully.
• Herding breeds and mixes may carry the MDR1 gene variant, which affects how this drug is cleared. Testing is a cheek swab.
• Fever or lethargy in the week or two after treatment is an urgent call.

Detailed explanation

How it works

Vinblastine is a vinca alkaloid. When a cell prepares to divide, it assembles microtubules into a spindle that pulls the duplicated chromosomes apart. Vinblastine binds to tubulin, the protein those microtubules are built from, disrupting spindle formation and arresting the cell cycle (Matsuyama et al., 2026).

Because it targets division rather than cancer specifically, the body's other rapidly dividing populations feel it too. Bone marrow first and foremost, which is where the characteristic side effect comes from.

You'll notice hospitals write the name oddly, as vinBLAStine and vinCRIStine, with the middle letters capitalized. That's a deliberate safety convention called tall-man lettering, used to prevent dispensing errors between drugs whose names are easy to confuse. It's a good sign, not a typo.

What it's used for

Mast cell tumors. This is the main use. Vinblastine appears in protocols for high-risk mast cell tumors, usually alongside prednisone. It can be given after surgery to lower the chance the tumor comes back or spreads, or as treatment for a tumor that can't be removed.

A quick note on grade, since it comes up constantly here. When a pathologist examines a mast cell tumor, they assign it a grade describing how aggressive it looks under the microscope. Grade 1 or low grade tumors usually behave well. Grade 3 or high grade tumors are the ones most likely to spread, and they're the dogs chemotherapy is aimed at.

The evidence has built up over about twenty-five years. An early series of 41 dogs treated with prednisone and vinblastine reported a 47 percent response rate among dogs with measurable disease (Thamm et al., 1999). A later study followed 61 dogs given vinblastine and prednisone after surgery. Half the dogs went more than 1,305 days, roughly three and a half years, before the cancer returned, and 65 percent were still alive at the three-year mark. Side effects showed up in 26 percent of dogs and were mostly mild, though 6.5 percent developed severe neutropenia (Thamm et al., 2006). A separate analysis found that dogs with grade 3 tumors went significantly longer without recurrence, and lived significantly longer, when they received vinblastine and prednisone after surgery than when they had surgery alone. Some of those dogs also received radiation, so the chemotherapy isn't the only variable (Webster et al., 2008).

Used on its own against a tumor that's still present and measurable, results are more modest. A trial in 51 dogs with grade II or III tumors that couldn't be surgically removed tested two dose levels. Tumors shrank in 27 percent of dogs on the higher dose and 12 percent on the lower one, and only the higher dose cleared the bar the researchers had set for further study. The authors were careful to note the trial wasn't designed to formally compare the two groups, so the gap between those numbers shouldn't be read as a settled difference (Rassnick et al., 2008). This is part of why vinblastine is usually combined with something else rather than used alone.

Combination protocols. Vinblastine is often paired with prednisolone and sometimes with toceranib, a targeted drug. One retrospective series of 40 dogs on that three-drug combination reported responses in 90 percent of dogs with measurable disease (Olsen et al., 2018). Retrospective studies can't establish that a combination is better than its parts, but there's real interest here.

Other uses. Vinblastine has reported activity against bladder cancer, which you may hear called urothelial carcinoma, and in some lymphoma situations, including as a later option once other drugs have stopped working (Matsuyama et al., 2026). It is not, as noted above, a good first-choice substitute for vincristine in lymphoma.

The white blood cell issue

This is where vinblastine differs most from its sibling drug, and it's the thing worth building your expectations around.

Neutrophils are the white cells that fight bacterial infection. Vinblastine suppresses the bone marrow that produces them, and the count falls to its lowest point in the days after treatment. That's why the oncology service runs bloodwork before every dose rather than only when something seems wrong.

The numbers give a sense of the range. In 30 dogs completing a twelve-week vinblastine and prednisolone protocol for high-grade or metastatic mast cell tumors, 24 experienced at least one blood-count abnormality. Anemia was most common, affecting half the dogs, and nearly all of it was the mildest grade. Neutropenia affected 46.6 percent. Most of those cases were mild too, though four dogs reached grade III. Oncologists score side effects on a scale where grade I is barely noticeable and higher numbers mean more serious, so grade III is roughly where a team starts stepping in. Neutropenia clustered in weeks two and three. The authors concluded the protocol was well tolerated overall, with toxicity that was mostly low grade and didn't require major intervention (Soussa et al., 2024).

That last sentence matters. Common is not the same as dangerous. Most of these dogs were fine.

Small dogs deserve a separate mention. Much of the early dosing work on vinblastine was done in larger dogs. A 2026 study looked specifically at 40 dogs weighing under 10 kg receiving a single treatment. Neutropenia occurred in 82.5 percent, with grade 3 or 4 neutropenia in 32.5 percent, and febrile neutropenia, meaning fever alongside a very low count, in 5 percent. Gastrointestinal effects were mild by comparison: diarrhea in a quarter of dogs, inappetence and vomiting in under 10 percent each. The authors concluded that the dose escalation strategies described in larger dogs may not translate to smaller ones (Matsuyama et al., 2026).

If your dog is small, this is worth raising directly with your oncologist. It doesn't mean vinblastine is wrong for them. It means the monitoring conversation is a real conversation.

Why the catheter gets so much attention

Vinblastine is a vesicant. If any of the drug escapes the vein into the surrounding tissue during administration, it damages that tissue, and the injury can progress over the following days to swelling, ulceration, and tissue death.

Prevention is the whole game here. Veterinary oncology guidelines call for a clean-stick catheter placement, proper restraint, adequate flushing, and delivering the drug by hand rather than by pump (American Animal Hospital Association, 2026b). A clean stick means the vein was entered on the first attempt with no earlier punctures further up the same vessel, because a vein poked earlier in the day can leak from the old hole even when the new catheter sits perfectly.

That requirement explains what you'll see in the treatment room. Why they may refuse the leg that had blood drawn this morning. Why they start over rather than adjust a catheter that isn't quite right. Why a restless dog gets sedation instead of firmer holding. Why the injection is given slowly by someone watching the site rather than set up and left. What looks like fussiness is the actual safety step.

If your dog licks at a treatment site, limps on that leg, or develops redness, swelling, or scabbing in the days after an injection, call the oncology service rather than waiting. Mitigation works better the earlier it starts, and the response to a suspected leak is specific: the team withdraws what drug they can rather than flushing the area (American Animal Hospital Association, 2026a).

The gene test worth asking about

The MDR1 gene, now more properly called ABCB1, produces a protein that pumps certain drugs out of cells and helps clear them from the body. A mutation common in herding breeds produces a broken version of that pump.

Vinblastine is one of the drugs it normally handles. Washington State University, whose laboratory identified the mutation, lists vinblastine among the chemotherapy agents requiring dose reduction in dogs carrying one or two copies, in order to avoid severe toxicity (Washington State University, 2021).

The mutation is most prevalent in collies, at up to around 70 percent carrying at least one copy, and is common in other herding breeds including Australian Shepherds and Shetland Sheepdogs. It also appears in German Shepherds, Long-Haired Whippets, Silken Windhounds, and in up to 10 percent of mixed breed dogs, including dogs who don't obviously look like herding mixes (American Animal Hospital Association, 2025).

Testing is a cheek swab or blood sample and it's inexpensive. Ask your oncology service about turnaround time, since it varies by laboratory and needs to fit before treatment starts.

Other side effects

Stomach upset. Generally milder than with vincristine, which is one of vinblastine's advantages. Vomiting, soft stool, and reduced appetite can happen and are usually self-limiting.

Anemia. Common but usually mild, and it tends to build slowly over a course of treatment rather than appearing suddenly (Soussa et al., 2024).

Low platelets. Reported but uncommon, and generally mild when it occurs (Soussa et al., 2024).

Nerve effects. Less prominent than with vincristine, but vinca alkaloids as a class can affect nerves and gut motility. Weakness, an unusual gait, or straining to pass stool is worth reporting.

Hair coat changes. Dogs generally don't lose their coats. Breeds with continuously growing hair, such as Poodles, are the exception, and whiskers often thin.

Safety at home

Vinblastine is given at the hospital, so you won't handle the drug. You will handle your dog's waste for a period afterward.

Ask your oncology team for their specific guidance, which is normally a defined window of a few days during which you wear gloves to pick up stool, keep your dog from eliminating where children play, and wash your hands thoroughly. Pregnant people and anyone immunocompromised in the household should not handle waste during that window. Ordinary contact, petting and sharing space, is fine.

When to contact a veterinarian

Call immediately, including after hours, if in the days and weeks following a vinblastine treatment your dog:

• Develops a fever or feels hot and seems unwell. With a low neutrophil count this is an emergency, not something to watch overnight.
• Becomes lethargic, weak, or won't get up
• Stops eating for more than a day
• Vomits repeatedly, or has diarrhea lasting more than a day or containing blood
• Has pale gums, or seems to tire much faster than usual, which can signal anemia
• Shows redness, swelling, blistering, scabbing, or pain at or near the injection site, or limps on that leg
• Licks persistently at the treatment site
• Bruises easily, or you notice small red spots on the gums or belly
• Seems wobbly, weak in the limbs, or is straining to pass stool

Lethargy plus not eating in the couple of weeks after treatment is the pattern most worth a same-day call. The dangerous version and the harmless version look similar from the outside. The bloodwork is what separates them.

Questions to ask your veterinarian

• Should my dog be tested for the MDR1 (ABCB1) mutation before we start, given their breed or ancestry?
• My dog is small. Does their size change how you'll dose or monitor vinblastine?
• When will you check bloodwork after each treatment, and what happens if a count comes back low?
• What temperature counts as a fever, and do you want me taking my dog's temperature at home?
• Are we using vinblastine after surgery to reduce recurrence risk, or to treat tumor we can still see? What are we hoping for in my dog's case?
• Would adding another drug to vinblastine be worth considering for my dog, and what would that change about side effects?
• Which medications should I have at home before the first treatment rather than scrambling later?
• How long should I use gloves for waste handling, and should anyone in my household avoid it entirely?

Sources

American Animal Hospital Association. (2025). White feet don't treat: Considerations for dogs with MDR1 mutations. NEWStat. https://www.aaha.org/newstat/publications/white-feet-dont-treat-considerations-for-dogs-with-mdr1-mutations/

American Animal Hospital Association. (2026a). Chemotherapy extravasation management. 2026 AAHA Oncology Guidelines for Dogs and Cats. https://www.aaha.org/resources/2026-aaha-oncology-guidelines-for-dogs-and-cats/chemotherapy-extravasation-management/

American Animal Hospital Association. (2026b). Therapeutic modalities: Chemotherapy. 2026 AAHA Oncology Guidelines for Dogs and Cats. https://www.aaha.org/resources/2026-aaha-oncology-guidelines-for-dogs-and-cats/section-5-therapeutic-interventions/therapeutic-modalities-chemotherapy/

Harding, K., Bergman, N., Smith, A., Lindley, S., Szivek, A., Milner, R., Brawner, W., & Lejeune, A. (2018). Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Veterinary and Comparative Oncology, 16(4), 636–641. https://doi.org/10.1111/vco.12433

Matsuyama, F., Harada, K., Ichimata, M., Fukazawa, E., Katayama, R., & Kobayashi, T. (2026). Adverse events in small dogs treated with a single dose of vinblastine. Journal of Veterinary Internal Medicine, 40(2), aalag050. https://doi.org/10.1093/jvimsj/aalag050

Olsen, J. A., Thomson, M., O'Connell, K., & Wyatt, K. (2018). Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Veterinary Medicine and Science, 4(3), 237–251. https://doi.org/10.1002/vms3.106

Rassnick, K. M., Bailey, D. B., Flory, A. B., Balkman, C. E., Kiselow, M. A., Intile, J. L., & Autio, K. (2008). Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine, 22(6), 1390–1396. https://doi.org/10.1111/j.1939-1676.2008.0195.x

Soussa, R. W., Jaderberg, S., Williams, T. L., & Dobson, J. M. (2024). Vinblastine/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors. Journal of the American Veterinary Medical Association, 262(12), 1644–1649. https://doi.org/10.2460/javma.24.03.0214

Thamm, D. H., Mauldin, E. A., & Vail, D. M. (1999). Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992–1997). Journal of Veterinary Internal Medicine, 13(5), 491–497.

Thamm, D. H., Turek, M. M., & Vail, D. M. (2006). Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science, 68(6), 581–587. https://doi.org/10.1292/jvms.68.581

Washington State University. (2021). Is your pet at risk of an adverse reaction to common drugs? Washington Animal Disease Diagnostic Laboratory. https://waddl.vetmed.wsu.edu/2021/10/19/is-your-pet-at-risk-of-an-adverse-reaction-to-common-drugs/

Webster, J. D., Yuzbasiyan-Gurkan, V., Thamm, D. H., Hamilton, E., & Kiupel, M. (2008). Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Veterinary Research, 4, 32. https://doi.org/10.1186/1746-6148-4-32